Today: 9 June 2026
Ucore Rare Metals stock jumps again as Washington’s critical-minerals push heats up — what’s next
17 January 2026
2 mins read

Ucore Rare Metals stock jumps again as Washington’s critical-minerals push heats up — what’s next

Toronto, January 17, 2026, 13:19 EST — The market has closed.

  • Ucore Rare Metals wrapped up Friday with a 4.4% gain, pushing the Canada-listed stock higher for a second straight day.
  • The company praised U.S. actions under Section 232, the trade law linked to national security, aimed at processed critical minerals.
  • Traders are now focusing on updates from trade talks and any movement on a U.S. bill aimed at creating a $2.5 billion critical-minerals stockpile.

Ucore Rare Metals shares ended Friday’s session up 4.4% at C$9.43 on Canada’s TSX Venture Exchange, building on a 5.9% rise from Thursday. The momentum comes amid ongoing policy talk keeping rare-earth stocks active.

This shift is crucial as investors scramble to figure out which segments of the rare earth supply chain Washington aims to develop domestically—and which could face trade hurdles. Attention this week turned away from mining and onto processing, an area where the U.S. remains heavily dependent on imports.

On January 14, the White House issued a proclamation stating that the Commerce Department determined imports of processed critical minerals and related products pose a threat to U.S. national security. The proclamation calls for trade negotiations that could lead to tariffs or other measures. This action invokes Section 232, a U.S. trade law permitting import restrictions on national-security grounds.

Ucore, working on a rare earth processing project in Louisiana with its RapidSX separation technology, applauded the administration’s latest guidance. The company pointed to processing capacity as the key choke point in the supply chain. “Critical minerals security requires domestic processing capability that can be deployed quickly,” said chairman and CEO Pat Ryan. Ucore Rare Metals

Capitol Hill added another boost for the sector. On Thursday, a bipartisan group of U.S. lawmakers put forward a bill aiming to build a $2.5 billion stockpile of critical minerals. The proposal is designed to stabilize prices and spur domestic mining and refining efforts.

Peers added to the buzz. On Thursday, Energy Fuels released a bankable feasibility study for expanding rare earth processing at its White Mesa Mill in Utah, estimating capital costs around $410 million. CEO Mark S. Chalmers described the project as “on the cusp of solving America’s rare earth processing ‘bottleneck’.” Energy Fuels

Beyond the U.S., the hunt for supply is intensifying. Coal India is exploring rare earth partnerships in Australia, Russia, and regions of Africa, aiming to reduce India’s dependence on China’s supply chain.

Markets are closed for the weekend, leaving traders to set up for Monday’s open in Canada. The U.S. stock and bond markets will be shuttered on Monday, January 19, for Martin Luther King Jr. Day. However, the TSX and TSX Venture calendars don’t recognize the U.S. holiday and remain open.

The policy wave cuts both ways. Trade talks could stall, and any future shift toward tariffs or import restrictions hinges on negotiations that might shift tone abruptly. Meanwhile, rare earth processing projects remain burdened by lengthy timelines, plus risks around permits and funding.

Next week’s focus is clear: look for early signs from Commerce and the U.S. trade representative about how talks will proceed, plus whether the stockpile bill picks up momentum. Updates from companies like Ucore on project financing and construction will also be key. Investors are watching the clock, too—the administration’s proclamation requires a status report within 180 days of the January 14 announcement.

Stock Market Today

  • Proxy Adviser Supports Nanoco Group's Plan to Delist from LSE
    June 9, 2026, 9:17 AM EDT. Nanoco Group PLC, a nanotechnology firm, announced that independent proxy adviser Glass Lewis has recommended shareholders approve the company's resolution to delist from the London Stock Exchange (LSE). The move signals a significant shift for Nanoco, potentially changing its trading and regulatory environment. Shareholder approval for such a resolution typically permits a company to withdraw its shares from public exchange trading, often to pursue private ownership or alternative funding routes. This development follows Nanoco's strategic review and may impact investor access and share liquidity. The recommendation by Glass Lewis adds weight to the proposal ahead of the upcoming shareholder vote.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
IREN stock jumps 11% on analyst upgrade chatter — what matters before Nasdaq reopens
Previous Story

IREN stock jumps 11% on analyst upgrade chatter — what matters before Nasdaq reopens

PetroChina A-share stock price slips as LNG Canada stake-sale talk and oil swings set up Monday
Next Story

PetroChina A-share stock price slips as LNG Canada stake-sale talk and oil swings set up Monday

Go toTop